文献速递免疫规划传染病防控与疫情报告

间日疟原虫环子孢子蛋白肽段疫苗的保护效力研究

Protective efficacy of peptides from Plasmodium vivax circumsporozoite protein.
PubMed 文献 · Vaccine · 2020-05-08

本研究以Qβ病毒样颗粒为平台在小鼠中针对PvCSP肽段诱导高水平抗体,发现VK210与VK247等位变异株的最小肽段疫苗高度保护,非amer重复中AGDR为中和抗体靶点,缺失N端结构域的截短PvCSP保护力显著高于全长,而保守区RI、RII肽段无保护效力。

要点

  • VK210与VK247最小肽段Qβ疫苗在同源变异株攻击中高度保护。
  • AGDR为VK210非amer重复内中和抗体靶点,单独部分保护,与全长PvCSP联用增强效力。
  • 缺失N端结构域的截短PvCSP保护力显著高于全长PvCSP。

核心结论

  • 基于Qβ病毒样颗粒的PvCSP最小肽段疫苗可诱导高水平抗体并具保护效力。
  • AGDR表位部分保护且与全长PvCSP联用可增强保护。
  • 缺失N端结构域的截短PvCSP保护力显著优于全长。
  • 保守区RI、RII肽段无保护效力。

研究设计与样本

  • 小鼠实验研究,以Qβ病毒样颗粒为平台展示PvCSP来源肽段。
  • 使用表达同源PvCSP等位变异株的转基因伯氏疟原虫进行攻击。

主要发现

  • VK210与VK247最小肽段Qβ疫苗在同源变异株攻击中高度保护。
  • AGDR作为Qβ肽段疫苗提供部分保护,与全长PvCSP疫苗联用增强保护效力。
  • 截短PvCSP(缺失N端结构域)保护力显著高于全长PvCSP。
  • RI、RII保守区肽段Qβ疫苗不提供保护效力。

临床怎么用

  • 提示PvCSP疫苗开发可优先考虑最小保护性肽段及截短形式。
  • AGDR表位可作为联合疫苗设计的候选靶点。

局限性

  • 研究仅在小鼠中进行,结果尚未在人体验证。
  • 采用转基因伯氏疟原虫攻击模型,与自然间日疟原虫感染存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Vivax malaria is a major cause of morbidity and mortality worldwide, with several million clinical cases per year and 2.5 billion at risk of infection. A vaccine is urgently needed but the most advanced malaria vaccine, VMP001, confers only very low levels of protection against vivax malaria challenge in humans. VMP001 is based on the circumsporozoite protein (CSP) of Plasmodium vivax. Here a virus-like particle, Qβ, is used as a platform to generate very high levels of antibody against peptides from PvCSP in mice, in order to answer questions important to further development of P. vivax CSP (PvCSP) vaccines. Minimal peptides from the VK210 and VK247 allelic variants of PvCSP are found to be highly protective as Qβ-peptide vaccines, using transgenic P. berghei parasites expressing the homologous PvCSP allelic variant. A target of neutralising antibodies within the nonamer unit repeat of VK210, AGDR, is found, as a Qβ-peptide vaccine, to provide partial protection against malaria challenge, and enhances protective efficacy when combined with full-length PvCSP vaccination. A truncated form of PvCSP, missing the N-terminal domain, is found to confer much higher levels of protective efficacy than full-length PvCSP. Peptides derived from highly conserved areas of PvCSP, RI and RII, are found not to confer protective efficacy as Qβ-peptide vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Atcheson E, Reyes-Sandoval A. Protective efficacy of peptides from Plasmodium vivax circumsporozoite protein. Vaccine. 2020. PMID: 32402755. doi:10.1016/j.vaccine.2020.03.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。